Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has declared a cash dividend of $1.34 per share for the fourth quarter of 2026. This dividend will be payable on December 8, 2026, to shareholders who are on record by November 24, 2026. The announcement underscores the company's ongoing commitment to returning value to its shareholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • The dividend reflects the company's strong financial performance.
  • Shareholders will receive a consistent return on their investment.
  • The announcement demonstrates J&J's commitment to rewarding investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Icotrokinra
Phase 3 · Colitis, Ulcerative

Full Press Release Details

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare

Frequently Asked Questions

What is the dividend amount declared by JNJ?

Johnson & Johnson declared a dividend of $1.34 per share.

When will the dividend be paid?

The dividend will be payable on December 8, 2026.

What is the ex-dividend date for JNJ's dividend?

The ex-dividend date is November 24, 2026.

Who qualifies for the dividend payment?

Shareholders of record by November 24, 2026, will qualify.

ShareAdd on Google
Tags: JNJ dividend quarterly dividend shareholders 2026
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IcotrokinraPhase 3
Colitis, Ulcerative →

Catalyst track record

+26%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →